Printer Friendly

CANGUARD HEALTH TECHNOLOGIES INC. - ANNOUNCES DEPRENYL RESEARCH LTD. HAS REQUESTED POSTPONEMENT IN LAWSUIT

 CANGUARD HEALTH TECHNOLOGIES INC. - ANNOUNCES DEPRENYL
 RESEARCH LTD. HAS REQUESTED POSTPONEMENT IN LAWSUIT
 VANCOUVER, April 30 /PRNewswire/ -- Canguard Health Technologies Inc. (VSE: CGD) announced today that Deprenyl Research Ltd. (TSE: DEP; NASDAQ: DEPLF) has, for a second time, requested a postponement in the lawsuit over the allegation of process patent infringement. Court proceedings are set to resume on June 16 and 17, 1992. CANGUARD does not regard the delay as material since the lawsuit is no longer a key business issue. The Canguard Group is fully prepared and expects to win on the evidence.
 With no restrictions on the development, registration and commercialization of PARKINYL (deprenyl), sales of this drug by the Canguard Group are now scheduled to commence very soon.
 DOLOROL, CANGUARD'S pain reliever, is expected to be on the market later this year.
 Very shortly, CANGUARD expects to announce major developments for its third product, a novel anti-convulsant for world markets. Several more products are in the pipeline and CANGUARD is negotiating rights to an interesting psychiatric drug with anti-depressant properties.
 With the help of its corporate partner, Pharmascience Inc. of Montreal, CANGUARD is building a strong pharmaceutical business with a world mandate.
 -0- 4/30/92
 /CONTACT: John B. Armstrong, M.D., Ph.D., president of Canguard Health Technologies, 604-682-1777/
 (DEPLF) CO: Canguard Health Technologies Inc.; Deprenyl Research Ltd. ST: IN: MTC SU:


PS -- NY012 -- 4738 04/30/92 08:30 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:235
Previous Article:PACIFICARE HEALTH SYSTEMS ANNOUNCES POSSIBLE PUBLIC OFFERING
Next Article:ELI LILLY & CO. ENTERS INTO COLLABORATION WITH BIOJECT


Related Articles
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO COMMENTS ON DEPRENYL RESEARCH LTD. PRESS RELEASE
CANGUARD HEALTH TECHNOLOGIES INC. RESPONDS TO LAWSUIT ANNOUNCED IN PRESS ON DEC. 3
CANGUARD HEALTH TECHNOLOGIES ANNOUNCES LAWSUIT UPDATE
DEPRENYL ADJOURNS APPLICATION FOR INJUNCTION
CANGUARD HEALTH TECHNOLOGIES RESPONSE TO DEPRENYL RELEASE
CANGUARD AND DEPRENYL RESEARCH LAWSUIT ADJOURNED TODAY; NO RESTRICTIONS IMPOSED ON CANGUARD
CANGUARD SERVES NOTICE OF MOTION, FINAL AFFIDAVITS ON DEPRENYL RESEARCH; ANNOUNCES NEW BUSINESS DEVELOPMENTS
CANGUARD DEFEATS DEPRENYL RESEARCH ON CONTEMPT CHARGE
CANGUARD AND DEPRENYL RESEARCH HAVE COURT DATE ON APRIL 30
CANGUARD HEALTH TECHNOLOGIES INC. RELEASES DETAILS OF ANNUAL REPORT TO SHAREHOLDERS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters